Share this article

Apraglutide is under clinical development by Ironwood Pharmaceuticals and currently in Phase III for Short Bowel Syndrome. According to GlobalData, Phase III drugs for Short Bowel Syndrome have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Apraglutide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Apraglutide overview

Apraglutide (FE-203799) is under development for the treatment of short bowel syndrome intestinal failure (SBS-IF) and gastrointestinal acute graft versus host disease (GVHD). It is administered through subcutaneous route as a powder and solution for solution for injection. The drug candidate is a long acting synthetic peptide analogue of glucagon-like-peptide-2 (GLP-2) which acts on GLP-2 receptor. It is developed by using peptide technology. It was under development for the treatment of chemotherapy-induced gastro-intestinal mucositis.

Ironwood Pharmaceuticals overview

Ironwood Pharmaceuticals (Ironwood) is a healthcare company engaged in the discovery, development and commercialization of human therapeutics and innovative gastrointestinal product opportunities. The company’s pipeline products include linaclotide, and vascular or fibrotic programs. Ironwood offers its products under two brands- Linzess and Constella. The company generates a pipeline of early development candidates and discovery research programs in various therapeutic areas which include gastrointestinal (GI), central nervous system (CNS) and allergic disorders. The company’s portfolio includes CNP-104, CNP-104 and IW-3300. It has strategic partnerships with leading pharmaceutical companies such as AbbVie Inc, for the development and commercialization of linaclotide across the globe. The company operates in the US and Switzerland. Ironwood is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of Apraglutide’s drug-specific PTSR and LoA scores, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.